BlackRock Health Sciences Trust II Key Executives
This section highlights BlackRock Health Sciences Trust II's key executives, including their titles and compensation details.
Find Contacts at BlackRock Health Sciences Trust II
(Showing 0 of )
BlackRock Health Sciences Trust II Earnings
This section highlights BlackRock Health Sciences Trust II's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
BlackRock Health Sciences Trust II (BMEZ)
BlackRock Health Sciences Term Trust is a closed-end management investment company, which investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The company was founded on August 14, 2019 and is headquartered in Wilmington, DE.
$15.05
Stock Price
$1.52B
Market Cap
-
Employees
New York, NY
Location
Financial Statements
Access annual & quarterly financial statements for BlackRock Health Sciences Trust II, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Revenue | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $- | $- | $- | $- |
| Other Expenses | $- | $- | $- | $- |
| Operating Expenses | $- | $- | $- | $- |
| Cost and Expenses | $- | $- | $- | $- |
| Interest Income | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- |
| Depreciation and Amortization | $228.49K | $236.56K | $206.30K | $171.86K |
| EBITDA | $- | $- | $- | $- |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $- | $- | $- | $- |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $- | $- | $- | $- |
| Income Before Tax | $- | $- | $- | $- |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $- |
| Net Income | $- | $- | $- | $- |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-5.97 | $-2.55 | $11.63 | $1.45 |
| EPS Diluted | $-5.97 | $-2.55 | $11.63 | $1.45 |
| Weighted Average Shares Outstanding | 114.36M | 112.88M | 112.70M | 78.09M |
| Weighted Average Shares Outstanding Diluted | 114.36M | 112.88M | 112.70M | 78.09M |
| SEC Filing | Source | Source | Source | Source |
| Breakdown |
|---|
| Revenue |
| Cost of Revenue |
| Gross Profit |
| Gross Profit Ratio |
| Research and Development Expenses |
| General and Administrative Expenses |
| Selling and Marketing Expenses |
| Selling General and Administrative Expenses |
| Other Expenses |
| Operating Expenses |
| Cost and Expenses |
| Interest Income |
| Interest Expense |
| Depreciation and Amortization |
| EBITDA |
| EBITDA Ratio |
| Operating Income |
| Operating Income Ratio |
| Total Other Income Expenses Net |
| Income Before Tax |
| Income Before Tax Ratio |
| Income Tax Expense |
| Net Income |
| Net Income Ratio |
| EPS |
| EPS Diluted |
| Weighted Average Shares Outstanding |
| Weighted Average Shares Outstanding Diluted |
| SEC Filing |
Annual Balance Sheet
| Breakdown | December 31, 2020 | December 31, 2019 |
|---|---|---|
| Cash and Cash Equivalents | $33.69K | $501.31K |
| Short Term Investments | $- | $- |
| Cash and Short Term Investments | $33.69K | $501.31K |
| Net Receivables | $375.66K | $574.41K |
| Inventory | $- | $- |
| Other Current Assets | $- | $- |
| Total Current Assets | $409.35K | $1.08M |
| Property Plant Equipment Net | $- | $- |
| Goodwill | $- | $- |
| Intangible Assets | $- | $- |
| Goodwill and Intangible Assets | $- | $- |
| Long Term Investments | $3.07B | $1.72B |
| Tax Assets | $- | $- |
| Other Non-Current Assets | $-3.07B | $-1.72B |
| Total Non-Current Assets | $3.07B | $1.72B |
| Other Assets | $19.40M | $8.75M |
| Total Assets | $3.09B | $1.73B |
| Account Payables | $1.76M | $1.52M |
| Short Term Debt | $- | $- |
| Tax Payables | $- | $- |
| Deferred Revenue | $- | $- |
| Other Current Liabilities | $-1.76M | $-1.52M |
| Total Current Liabilities | $1.76M | $1.52M |
| Long Term Debt | $- | $- |
| Deferred Revenue Non-Current | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- |
| Other Non-Current Liabilities | $- | $- |
| Total Non-Current Liabilities | $- | $- |
| Other Liabilities | $64.01M | $93.49M |
| Total Liabilities | $64.01M | $93.49M |
| Preferred Stock | $- | $- |
| Common Stock | $1.51B | $1.52B |
| Retained Earnings | $1.52B | $117.28M |
| Accumulated Other Comprehensive Income Loss | $- | $- |
| Other Total Stockholders Equity | $- | $- |
| Total Stockholders Equity | $3.02B | $1.64B |
| Total Equity | $3.02B | $1.64B |
| Total Liabilities and Stockholders Equity | $3.09B | $1.73B |
| Minority Interest | $- | $- |
| Total Liabilities and Total Equity | $3.09B | $1.73B |
| Total Investments | $3.07B | $1.72B |
| Total Debt | $- | $- |
| Net Debt | $-33.69K | $-501.31K |
Balance Sheet Charts
| Breakdown | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | April 30, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $33.69K | $- | $501.31K | $- | $100.00K |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $33.69K | $- | $501.31K | $- | $100.00K |
| Net Receivables | $375.66K | $1.18M | $574.41K | $1.48M | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $- | $- | $- | $- | $- |
| Total Current Assets | $409.35K | $1.18M | $1.08M | $1.48M | $100.00K |
| Property Plant Equipment Net | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $3.07B | $2.06B | $1.72B | $1.58B | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $-3.07B | $-2.06B | $-1.72B | $-1.58B | $- |
| Total Non-Current Assets | $3.07B | $2.06B | $1.72B | $1.58B | $- |
| Other Assets | $19.40M | $9.00M | $8.75M | $- | $100.00K |
| Total Assets | $3.09B | $2.07B | $1.73B | $1.58B | $100.00K |
| Account Payables | $1.76M | $1.56M | $1.52M | $163.40M | $- |
| Short Term Debt | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $-1.76M | $-1.56M | $-1.52M | $-163.40M | $- |
| Total Current Liabilities | $1.76M | $1.56M | $1.52M | $163.40M | $- |
| Long Term Debt | $- | $127.49K | $- | $7.01M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $127.49K | $- | $7.01M | $- |
| Other Liabilities | $64.01M | $50.22M | $93.49M | $2.07M | $- |
| Total Liabilities | $64.01M | $51.91M | $93.49M | $172.49M | $- |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.51B | $1.52B | $1.52B | $1.40B | $100.00K |
| Retained Earnings | $1.52B | $500.70M | $117.28M | $6.43M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- |
| Other Total Stockholders Equity | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $3.02B | $2.02B | $1.64B | $1.41B | $100.00K |
| Total Equity | $3.02B | $2.02B | $1.64B | $1.41B | $100.00K |
| Total Liabilities and Stockholders Equity | $3.09B | $2.07B | $1.73B | $1.58B | $100.00K |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.09B | $2.07B | $1.73B | $1.58B | $100.00K |
| Total Investments | $3.07B | $2.06B | $1.72B | $1.58B | $- |
| Total Debt | $- | $127.49K | $- | $7.01M | $- |
| Net Debt | $-33.69K | $127.49K | $-501.31K | $7.01M | $-100.00K |
Annual Cash Flow
| Breakdown | December 31, 2020 | December 31, 2019 |
|---|---|---|
| Net Income | $1.49B | $113.23M |
| Depreciation and Amortization | $- | $- |
| Deferred Income Tax | $- | $- |
| Stock Based Compensation | $- | $- |
| Change in Working Capital | $-66.76M | $70.10M |
| Accounts Receivables | $- | $- |
| Inventory | $- | $- |
| Accounts Payables | $- | $- |
| Other Working Capital | $-66.76M | $- |
| Other Non Cash Items | $-1.31B | $-1.70B |
| Net Cash Provided by Operating Activities | $107.17M | $-1.52B |
| Investments in Property Plant and Equipment | $- | $- |
| Acquisitions Net | $- | $- |
| Purchases of Investments | $- | $- |
| Sales Maturities of Investments | $- | $- |
| Other Investing Activities | $- | $- |
| Net Cash Used for Investing Activities | $- | $- |
| Debt Repayment | $- | $- |
| Common Stock Issued | $- | $- |
| Common Stock Repurchased | $- | $- |
| Dividends Paid | $- | $- |
| Other Financing Activities | $-96.98M | $1.52B |
| Net Cash Used Provided by Financing Activities | $-96.98M | $1.52B |
| Effect of Forex Changes on Cash | $60 | $19 |
| Net Change in Cash | $10.18M | $9.15M |
| Cash at End of Period | $19.44M | $9.25M |
| Cash at Beginning of Period | $9.25M | $100.00K |
| Operating Cash Flow | $107.17M | $-1.52B |
| Capital Expenditure | $- | $- |
| Free Cash Flow | $107.17M | $-1.52B |
Cash Flow Charts
| Breakdown |
|---|
| Net Income |
| Depreciation and Amortization |
| Deferred Income Tax |
| Stock Based Compensation |
| Change in Working Capital |
| Accounts Receivables |
| Inventory |
| Accounts Payables |
| Other Working Capital |
| Other Non Cash Items |
| Net Cash Provided by Operating Activities |
| Investments in Property Plant and Equipment |
| Acquisitions Net |
| Purchases of Investments |
| Sales Maturities of Investments |
| Other Investing Activities |
| Net Cash Used for Investing Activities |
| Debt Repayment |
| Common Stock Issued |
| Common Stock Repurchased |
| Dividends Paid |
| Other Financing Activities |
| Net Cash Used Provided by Financing Activities |
| Effect of Forex Changes on Cash |
| Net Change in Cash |
| Cash at End of Period |
| Cash at Beginning of Period |
| Operating Cash Flow |
| Capital Expenditure |
| Free Cash Flow |
BlackRock Health Sciences Trust II Dividends
Explore BlackRock Health Sciences Trust II's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
0.00x
BlackRock Health Sciences Trust II Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.1763 | $0.1763 | March 14, 2025 | March 14, 2025 | March 31, 2025 | March 03, 2025 |
| $0.1773 | $0.1773 | February 14, 2025 | February 14, 2025 | February 28, 2025 | February 03, 2025 |
| $0.17819 | $0.17819 | January 15, 2025 | January 15, 2025 | January 31, 2025 | January 02, 2025 |
| $0.17809 | $0.17809 | December 16, 2024 | December 16, 2024 | December 23, 2024 | December 06, 2024 |
| $0.1769 | $0.1769 | November 15, 2024 | November 15, 2024 | November 29, 2024 | November 01, 2024 |
| $0.17599 | $0.17599 | October 15, 2024 | October 15, 2024 | October 31, 2024 | September 12, 2024 |
| $0.17602 | $0.17602 | September 16, 2024 | September 16, 2024 | September 30, 2024 | September 03, 2024 |
| $0.17641 | $0.17641 | August 15, 2024 | August 15, 2024 | August 30, 2024 | August 01, 2024 |
| $0.17741 | $0.17741 | July 15, 2024 | July 15, 2024 | July 31, 2024 | July 01, 2024 |
| $0.17887 | $0.17887 | June 14, 2024 | June 14, 2024 | June 28, 2024 | May 20, 2024 |
| $0.08983 | $0.08983 | May 14, 2024 | May 15, 2024 | May 31, 2024 | May 01, 2024 |
| $0.09015 | $0.09015 | April 12, 2024 | April 15, 2024 | April 30, 2024 | April 01, 2024 |
| $0.09003 | $0.09003 | March 14, 2024 | March 15, 2024 | March 28, 2024 | March 01, 2024 |
| $0.09044 | $0.09044 | February 14, 2024 | February 15, 2024 | February 29, 2024 | February 01, 2024 |
| $0.09091 | $0.09091 | January 11, 2024 | January 12, 2024 | January 31, 2024 | January 02, 2024 |
| $0.0916 | $0.0916 | December 14, 2023 | December 15, 2023 | December 20, 2023 | December 05, 2023 |
| $0.09269 | $0.09269 | November 14, 2023 | November 15, 2023 | November 30, 2023 | November 01, 2023 |
| $0.09318 | $0.09318 | October 13, 2023 | October 16, 2023 | October 31, 2023 | October 02, 2023 |
| $0.145 | $0.145 | September 14, 2023 | September 15, 2023 | September 29, 2023 | September 01, 2023 |
| $0.145 | $0.145 | August 14, 2023 | August 15, 2023 | August 31, 2023 | August 01, 2023 |
BlackRock Health Sciences Trust II News
Read the latest news about BlackRock Health Sciences Trust II, including recent articles, headlines, and updates.
BlackRock Health Sciences Term Trust (BMEZ) Commences Tender Offer for up to 40% of outstanding common shares
NEW YORK--(BUSINESS WIRE)---- $BMEZ--BlackRock Health Sciences Term Trust (NYSE: BMEZ) announced today the commencement, expiration and pricing dates of the previously announced offer to repurchase up to 40% of outstanding common shares at a price per share equal to 99.5% of the Fund's net asset value per common share as determined on the pricing date (the “Tender Offer”). The Fund's Board of Trustees have authorized the Tender Offer with the anticipated commencement, expiration and pricing dates outline.
CEF Weekly Review: Will BTT Terminate?
We review the CEF market valuation and performance through the first week of March and highlight recent market action. Nearly all CEF sectors were down due to poor risk sentiment, but year-to-date performance remains mostly positive, led by EM assets. BlackRock Municipal 2030 Target Term renewed its share repurchase program.
BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund
Fear of a looming recession has investors seeking defensive sectors like Healthcare, which benefits from positive secular trends and offers high-yield dividend stocks. The BlackRock Health Sciences Term Trust provides high-yield income through healthcare equities and an option writing strategy, with a current distribution rate of 13.6%. BMEZ's top holdings, including Intuitive Surgical, argenx SE, and Alnylam Pharmaceuticals, show strong growth potential, despite past underperformance due to market conditions.
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
NEW YORK--(BUSINESS WIRE)---- $BBN--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYSE: BGR), BlackRock Enhanced International Dividend Trust (NYSE: BGY), BlackRock Health Sciences Trust (NYSE: BME), BlackRock Health Sciences Term Trust (NYSE: BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE: BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE: BUI), Bla.
CEF Weekly Review: Explaining Preferred CEFs Double-Digit Gains
We review the CEF market valuation and performance through the first week of February and highlight recent market action. CEFs had a strong week, with most sectors in the green, driven by EM Equity and Muni sectors, and year-to-date gains in both NAVs and discounts. We take a look at why preferred CEFs have sharply outperformed their ETF counterparts last year.
BlackRock Announces Board Approval of New Tender Offers for BlackRock Innovation and Growth Term Trust (BIGZ) and BlackRock Health Sciences Term Trust (BMEZ)
NEW YORK--(BUSINESS WIRE)---- $BIGZ--BlackRock Advisors, LLC (“BlackRock”) announced today that the Board of Trustees of BlackRock Innovation and Growth Term Trust (NYSE: BIGZ) has approved a tender offer to repurchase 50% of BIGZ's outstanding shares, and that the Board of Trustees of BlackRock Health Sciences Term Trust (NYSE: BMEZ) has approved a tender offer to repurchase 40% of BMEZ's outstanding shares, in each case at a price per share equal to 99.5% of the applicable Fund's net asset value per co.
BMEZ: 12% Discount, High Yield On Healthcare Monthly Payer
BMEZ employs an option writing strategy and has a 12-year limited term, with a recent increase in monthly distributions to 12% of NAV. This article details BMEZ's top holdings, sector and geographic exposure and changes in 2024. Dividend yield, earnings, taxes, expenses, and average volume are also covered.
11 Closed-End Fund Buys In The Month Of November 2024
This month, I've added to 11 different positions, but most of these were related to repurchases after the BlackRock tender offers. While I added to 11 different positions, these were all positions I had already held previously, so there were no new positions this month. In fact, I sold out of a fund to consolidate my holdings and reduce the number of funds held, as I did last month as well.
BMEZ: Remains Attractive With A Deep Discount
BMEZ offers a more speculative but attractive healthcare investment with significant biotech exposure, mid-cap, small-cap, and private investments. The fund's discount remains appealing, that is despite narrowing from around 18% to ~10% from the start of the year. The fund has employed a 12% managed distribution as well as being one of the several BlackRock funds to have a discount management program in place.
BMEZ: A 14.2% Yielding CEF With An 11.85% Discount And Activist Pressure
BMEZ trades at an 11.85% discount to NAV, offering a high distribution rate of 14.2% annually, despite high fees and management concerns. The fund focuses on healthcare and technology, with 8.3% in private investments, and employs a call-selling strategy on 23% of its holdings. Activist pressure from Saba Capital and others could lead to future measures like distribution increases, fee reductions, or management changes.
9 Closed-End Fund Buys In The Month Of August 2024
The broader equity market saw declines in early August but ended near all-time highs to finish off the month. I put some capital to work this month at the low, but not as much as I had planned initially, as the market swiftly recovered. Most of the moves this month were corporate action-driven events, primarily the BlackRock tender offers, as we finished up the first measurement period.
Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers: BMEZ, BME, BGY
NEW YORK--(BUSINESS WIRE)---- $BGY--The BlackRock closed-end funds (the “Funds”) listed below announced today the expiration and preliminary results of each Fund's tender offer (each, a “Tender Offer”) for up to 2.5% of its outstanding common shares (the “Shares”). Each Tender Offer commenced on July 18, 2024 and expired at 5:00 p.m. Eastern time on August 19, 2024. Based on preliminary information, the number of Shares properly tendered for each Fund and not withdrawn is noted in the table below. Fund.
BMEZ: Option Income CEF With Steep NAV Discount Ready For Biotech Recovery
BlackRock raised dividends for BMEZ, offering a monthly distribution of $0.1789 with a 14.24% yield, showing confidence in the fund's future. BMEZ shares have been bought back multiple times in 2024, indicating strong tailwinds for the fund's stock price. BMEZ is a buy with high-yield and unique sector diversification in the biotechnology industry, expected to rebound significantly in 2024.
BlackRock Announces Increased Distribution Rates for Certain Closed-End Funds
NEW YORK--(BUSINESS WIRE)--Today, the Board of Trustees of each of BlackRock ESG Capital Allocation Term Trust (NYSE: ECAT), BlackRock Capital Allocation Term Trust (NYSE: BCAT), BlackRock Health Sciences Term Trust (NYSE: BMEZ), BlackRock Science and Technology Term Trust (NYSE: BSTZ), and BlackRock Innovation and Growth Term Trust (NYSE: BIGZ) (each a “Fund,” and collectively the “Funds”) announced increased distribution rates under each Fund’s managed distribution plan (“Plan”). Each Fund has adopted a Plan to support a level monthly distribution of income, capital gains and/or return of capital. “We have taken this step to support shareholders of these Funds, consistent with our goal of delivering long-term value. We are focused on enhancing returns for our closed-end fund shareholders and helping them plan for their financial futures,” said R. Glenn Hubbard, Chair of the Board of BlackRock Closed-End Funds Effective today, each of ECAT and BCAT will pay monthly distributions to shareholders at an annual rate of 20% of the Fund’s 12-month rolling average daily net asset value to be calculated 5 business days prior to declaration date. Each of BMEZ, BSTZ and BIGZ will pay monthly distributions to shareholders at an annual rate of 12% of the Fund’s 12-month rolling average daily net asset value to be calculated 5 business days prior to declaration date. For example, the July 2024 distribution will be calculated based on the average net asset value from June 22, 2023 to June 21, 2024. Each month this formula will be applied, and the distribution per share will be re-set and announced on the distribution declaration date. Declaration: 5/20/2024 Ex-Date: 6/14/2024 Record: 6/14/2024 Payable: 6/28/2024 Fund NYSE Ticker Annualized Distribution Rate as a Percentage of 12- Month Average NAV Distribution Amount per Share Change in Monthly Distribution Amount Per Share from Prior Distribution BlackRock ESG Capital Allocation Term Trust* ECAT 20.00% $0.296930 +$0.146930 (+98%) BlackRock Capital Allocation Term Trust* BCAT 20.00% $0.285390 +$0.157890 (+124%) BlackRock Health Sciences Term Trust* BMEZ 12.00% $0.178870 +$0.089040 (+99%) BlackRock Science and Technology Term Trust* BSTZ 12.00% $0.211250 +$0.106090 (+101%) BlackRock Innovation and Growth Term Trust* BIGZ 12.00% $0.088870 +$0.044430 (+100%) *In order to comply with the requirements of Section 19 of the Investment Company Act of 1940, as amended (the “1940 Act”), each of the Funds above posted to the DTC bulletin board and sent to its shareholders of record as of the applicable record date a Section 19 notice with the previous distribution payment. The Section 19 notice was provided for informational purposes only and not for tax reporting purposes. This information can be found in the “Closed-End Funds” section of www.blackrock.com. As applicable, the final determination of the source and tax characteristics of all distributions in 2024 will be made after the end of the year. BlackRock ESG Capital Allocation Term Trust (NYSE: ECAT), BlackRock Capital Allocation Term Trust (NYSE: BCAT), BlackRock Health Sciences Term Trust (NYSE: BMEZ), BlackRock Science and Technology Term Trust (NYSE: BSTZ), and BlackRock Innovation and Growth Term Trust (NYSE: BIGZ) have adopted a managed distribution plan (a “Plan”) to support a monthly distribution based on the annual rates in the table above of each Fund’s 12-month rolling average daily net asset value calculated 5 business days prior to declaration date of each distribution. The June 2024 distribution for each of ECAT, BCAT, BSTZ, BMEZ and BIGZ was calculated based on the average net asset value from May 11, 2023 to May 10, 2024. Below are the 12-month rolling average daily net asset values used to calculate ECAT, BCAT, BSTZ, BMEZ and BIGZ’s June distributions: ECAT: $17.815754 BCAT: $17.123095 BMEZ: $17.886111 BSTZ: $21.124683 BIGZ: $8.886865 The annual distribution rate is subject to change at the discretion of each Fund’s Board of Trustees. Under its Plan, each Fund will distribute all available investment income to its shareholders, consistent with its investment objectives and as required by the Internal Revenue Code of 1986, as amended. If sufficient investment income is not available for a monthly distribution, a Fund will distribute long-term capital gains and/or return of capital in order to maintain its stated fixed annual distribution rate under the Plan. The Funds’ estimated sources of the distributions paid this month and for their current fiscal year are as follows: Estimated Allocations as of April 30, 2024 Fund Distribution Net Income Net Realized Short- Term Gains Net Realized Long- Term Gains Return of Capital ECAT1 $0.150000 $0.040696 (27%) $0 (0%) $0 (0%) $0.109304 (73%) BCAT1 $0.127500 $0.056687 (44%) $0 (0%) $0 (0%) $0.070813 (56%) BMEZ1 $0.089830 $0 (0%) $0 (0%) $0 (0%) $0.089830 (100%) BSTZ1 $0.105160 $0 (0%) $0 (0%) $0 (0%) $0.105160 (100%) BIGZ1 $0.044440 $0 (0%) $0 (0%) $0 (0%) $0.044440 (100%) Estimated Allocations for the Fiscal Year through April 30, 2024 Fund Distribution Net Income Net Realized Short- Term Gains Net Realized Long- Term Gains Return of Capital ECAT1 $0.750000 $0.016513 (2%) $0 (0%) $0 (0%) $0.733487 (98%) BCAT1 $0.637500 $0.032121 (5%) $0 (0%) $0 (0%) $0.605379 (95%) BMEZ1 $0.451360 $0 (0%) $0 (0%) $0 (0%) $0.451360 (100%) BSTZ1 $0.519130 $0 (0%) $0 (0%) $0 (0%) $0.519130 (100%) BIGZ1 $0.222760 $0 (0%) $0 (0%) $0 (0%) $0.222760 (100%) 1The Fund estimates that it has distributed more than its income and net-realized capital gains in the current fiscal year; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment is paid back to the shareholder. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with ‘yield’ or ‘income’. When distributions exceed total return performance, the difference will reduce the Fund’s net asset value per share. The amounts and sources of distributions reported are only estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon each Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes. Fund Performance and Distribution Rate Information: Fund Average annual total return (in relation to NAV) for the 5-year period ending on 4/30/2024 Annualized current distribution rate expressed as a percentage of NAV as of 4/30/2024 Cumulative total return (in relation to NAV) for the fiscal year through 4/30/2024 Cumulative fiscal year distributions as a percentage of NAV as of 4/30/2024 ECAT* 4.73% 9.92% 4.13% 3.31% BCAT* 3.83% 8.83% 3.72% 2.94% BMEZ* 4.32% 6.23% (1.17)% 2.09% BSTZ* 9.52% 5.99% 0.67% 1.97% BIGZ* (16.82)% 6.19% (2.33)% 2.07% *Fund launched within the past 5 years; the performance and distribution rate information presented for this Fund reflects data from inception to 4/30/2024. Shareholders should not draw any conclusions about a Fund’s investment performance from the amount of the Fund’s current distributions or from the terms of the Fund’s Plan. The annual distribution rate and amount distributed per share under a Plan is subject to change at the discretion each Fund’s Board. Each Plan will be subject to ongoing review by the Board to determine whether the Plan should be continued, modified or terminated. The Board may amend the terms of a Plan or suspend or terminate a Plan at any time without prior notice to the Fund’s shareholders if it deems such actions to be in the best interest of the Fund or its shareholders. The amendment or termination of a Plan could have an adverse effect on the market price of the Fund's shares. About BlackRock BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate Availability of Fund Updates BlackRock will update performance and certain other data for the Funds on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Funds. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Funds and does not, and is not intended to, incorporate BlackRock’s website in this release. Forward-Looking Statements This press release, and other statements that BlackRock or a Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to a Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions. BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance. With respect to the Funds, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Funds or in a Fund’s net asset value; (2) the relative and absolute investment performance of a Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to a Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions. Annual and Semi-Annual Reports and other regulatory filings of the Funds with the Securities and Exchange Commission (“SEC”) are accessible on the SEC's website at www.sec.gov and on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Funds. The information contained on BlackRock’s website is not a part of this press release.
Private Advisor Group LLC Has $524,000 Stock Holdings in BlackRock Health Sciences Term Trust (NYSE:BMEZ)
Private Advisor Group LLC raised its stake in BlackRock Health Sciences Term Trust (NYSE:BMEZ – Free Report) by 24.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,791 shares of the company’s stock after purchasing an additional 6,935 shares during the period. Private Advisor Group LLC’s holdings in BlackRock Health Sciences Term Trust were worth $524,000 at the end of the most recent quarter. Other large investors also recently modified their holdings of the company. B. Riley Wealth Advisors Inc. raised its holdings in BlackRock Health Sciences Term Trust by 4.8% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 17,363 shares of the company’s stock valued at $250,000 after acquiring an additional 796 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of BlackRock Health Sciences Term Trust by 24.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 4,792 shares of the company’s stock worth $70,000 after buying an additional 930 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in shares of BlackRock Health Sciences Term Trust by 4.0% in the third quarter. Janney Montgomery Scott LLC now owns 30,936 shares of the company’s stock valued at $446,000 after acquiring an additional 1,199 shares in the last quarter. LPL Financial LLC raised its stake in BlackRock Health Sciences Term Trust by 0.5% in the 3rd quarter. LPL Financial LLC now owns 274,665 shares of the company’s stock worth $3,958,000 after purchasing an additional 1,231 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in BlackRock Health Sciences Term Trust by 22.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 25,955 shares of the company’s stock valued at $374,000 after purchasing an additional 4,745 shares during the period. Insider Activity In other news, major shareholder Saba Capital Management, L.P. acquired 193,297 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were acquired at an average cost of 15.92 per share, with a total value of 3,077,288.24. Following the completion of the purchase, the insider now directly owns 19,578,308 shares of the company’s stock, valued at approximately 311,686,663.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders bought 701,207 shares of company stock worth $11,338,909. BlackRock Health Sciences Term Trust Trading Down 0.1 % NYSE BMEZ opened at 15.10 on Monday. The company has a 50 day moving average of 15.46 and a 200-day moving average of 15.10. BlackRock Health Sciences Term Trust has a 1-year low of 12.93 and a 1-year high of 16.59. BlackRock Health Sciences Term Trust Announces Dividend The company also recently announced a monthly dividend, which will be paid on Friday, May 31st. Shareholders of record on Wednesday, May 15th will be issued a $0.09 dividend. This represents a $1.08 annualized dividend and a yield of 7.15%. The ex-dividend date is Tuesday, May 14th. BlackRock Health Sciences Term Trust Company Profile (Free Report) BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.
BMEZ: Higher Risk Healthcare Exposure With Potential For Higher Reward
BlackRock Health Sciences Term Trust has seen its discount narrow somewhat since our last update, but it remains attractive still. BMEZ utilizes a covered call writing strategy and also provides some private investments to help deliver performance. The biotech space has performed rather poorly in the last several years but 2024 seems to be a bit more promising.
BMEZ: 6% Yield Healthcare Fund And Alternatives
The Healthcare sector has trailed the Tech-heavy S&P 500 in the past 10 years, but has recently seen a boost in performance. BlackRock Health Sciences Term Trust and BlackRock Health Sciences Trust are two funds that invest in the healthcare sector. BMEZ focuses on "cutting edge" health sciences stocks, while BME focuses on large cap healthcare names.
Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds
NEW YORK--(BUSINESS WIRE)--Certain BlackRock closed-end funds (the “Funds”) announced distributions today as detailed below. Municipal Funds: Declaration- 3/1/2024 Ex-Date- 3/14/2024 Record- 3/15/2024 Payable- 4/1/2024 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.052500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.043500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Fund, Inc.
5 Closed-End Fund Buys In The Month Of December 2023 (Plus 1 Sell)
Equity and fixed-income markets had another strong month in December, driven by continuing retreating risk-free Treasury rates. We even saw an improvement in the breadth of the overall market, with broader participation lifting some of the beaten-down sectors for the year. That said, closed-end fund discounts remain historically wide, and that continues to drive opportunity in the CEF wrapper.
Similar Companies
Virtus Artificial Intelligence & Technology Opportunities Fund
AIO
Price: $21.40
Market Cap: $734.90M
Blackrock Resources & Commodities Strategy Trust
BCX
Price: $9.37
Market Cap: $751.45M
BlackRock Utilities, Infrastructure & Power Opportunities Trust
BUI
Price: $22.70
Market Cap: $510.19M
Neuberger Berman Next Generation Connectivity Fund Inc.
NBXG
Price: $12.68
Market Cap: $998.70M
Columbia Seligman Premium Technology Growth Fund
STK
Price: $29.13
Market Cap: $482.18M
Related Metrics
Explore detailed financial metrics and analysis for BMEZ.